MAPK12 and diffuse large B-cell lymphoma: The results revealed that patients with DLBCL who exhibited high MAPK12 expression (n = 66) had significantly lower survival rates compared to those with low MAPK12 expression (n = 87) (p = 0.0016) (Fig. 3a).